<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Technetium Tc-99m pyrophosphate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Technetium Tc-99m pyrophosphate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Technetium Tc-99m pyrophosphate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="17086" href="/d/html/17086.html" rel="external">see "Technetium Tc-99m pyrophosphate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F48894288"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Technescan PYP</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13210218"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F13210271"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d04f6ea6-b23c-46d6-ad95-04e3b6062ebe">Blood pool imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Blood pool imaging:</b>
<b>IV:</b> Between 1/3 (0.33) and whole vial of stannous pyrophosphate, followed by 15 to 20 mCi (555 to 740 MBq) of sodium pertechnetate Tc 99m.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33fbe290-56ea-4a56-9063-02386169097e">Myocardial infarction imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myocardial infarction imaging: IV:</b> 10 to 15 mCi (370 to 555 MBq).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c6e41a7c-edc7-4640-a258-58aa015ccc4a">Skeletal imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skeletal imaging:</b>
<b>IV:</b> 5 to 15 mCi (185 to 555 MBq).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990989"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50988167"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F57604665"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F50470833"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Flushing, hypotension</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Chills, dizziness</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F49659040"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling.</p></div>
<div class="block war drugH1Div" id="F13210219"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. <b>Note:</b> Contents of kit are not radioactive; however adequate shielding is required after addition of radioactive material.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Brain imaging should precede bone imaging to avoid false negatives or false positives. Patients should be adequately hydrated prior to and after dosing; instruct patients to void frequently for 4 to 6 hours following administration to decrease radiation exposure to the bladder. If a brain scan is anticipated, it should precede bone imaging procedures.</p></div>
<div class="block foc drugH1Div" id="F46170881"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Technescan PYP: Sodium pyrophosphate 11.9 mg [pyrogen free; vial contents to be combined with Technetium Tc 99m pertechnetate sodium (not included)]</p></div>
<div class="block geq drugH1Div" id="F48875157"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block adm drugH1Div" id="F20223270"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV:</p>
<p style="text-indent:-2em;margin-left:2em;">Blood pool imaging: Administer stannous pyrophosphate IV 15 to 30 minutes prior to IV sodium pertechnetate Tc 99m. Inject by direct venipuncture. Avoid heparinized catheters. Perform cardiac imaging 10 minutes following sodium pertechnetate Tc 99m administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac and skeletal imaging: For IV administration (over 10 to 20 seconds); avoid heparinized catheters. Bone imaging is optimal 1 to 6 hours after administration; cardiac imaging is optimal 60 to 90 minutes after administration. Patients should be adequately hydrated before and after dosing; instruct patients to void as often as possible following administration to decrease radiation exposure to the bladder.</p>
<p style="text-indent:-2em;margin-left:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal.</p></div>
<div class="block use drugH1Div" id="F13210225"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Imaging agent:</b> Skeletal imaging agent to detect areas of altered osteogenesis; cardiac imaging agent used as an adjunctive agent for the diagnosis of acute myocardial infarction; blood pool imaging agent for gated blood pool imaging or detection of GI bleeding sites</p></div>
<div class="block mst drugH1Div" id="F13255278"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F57529646"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57529643"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53623760"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy status should be evaluated prior to use in women of reproductive potential (SNM 2010).</p>
<p style="text-indent:0em;margin-top:2em;">The manufacturer recommends elective studies be conducted during the first 10 days of the menstrual cycle in women of reproductive potential.</p></div>
<div class="block pri drugH1Div" id="F13210222"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Technetium Tc 99m can be detected in fetal tissue; the amount depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein 1999).</p>
<p style="text-indent:0em;margin-top:2em;">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (ACR-SPR 2018; Adelstein 1999; ICRP 2000; SNM 2010).</p></div>
<div class="block brc drugH1Div" id="F13210224"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends substituting formula for breastfeeding. Alternately, women can pump and store milk prior to the procedure, then bottle feed using the stored milk for a period of ≤12 hours after imaging with technetium Tc 99m pyrophosphate (Harding 1995).</p>
<p style="text-indent:-2em;margin-left:2em;">Elective diagnostic procedures should be delayed until breastfeeding has stopped (SNM 2010). Women who are breastfeeding and caring for individuals undergoing nuclear medicine procedures do not need any additional precautions (ABM [Mitchell 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion of technetium Tc 99m into colostrum is widely variable and information is limited; therefore, recommendations related to early breastfeeding cannot be made (Mountford 1989; Rubow 1994).</p></div>
<div class="block pha drugH1Div" id="F49661640"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Radioactive diagnostic agent which decays by isomeric transition to emit a photon that can be detected by imaging</p></div>
<div class="block phk drugH1Div" id="F49661641"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Physical: ~6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~40% within 24 hours)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23777217"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Technescan pyp</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Techne pyrophosphate kit</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-10331526">
<a name="10331526"></a>Adelstein SJ. Administered Radionuclides in Pregnancy. <i>Teratology</i>. 1999;59(4):236-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-pyrophosphate-drug-information/abstract-text/10331526/pubmed" id="10331526" target="_blank">10331526</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American College of Radiology (ACR), Society for Pediatric Radiology (SPR). ACR–SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation (resolution 39). Revised 2018. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Pregnant-Pts.pdf?la=en. Accessed February 24, 2020.</div>
</li>
<li>
<div class="reference">
                  Harding LK, Bossuyt S, Pellet C, et al. Recommendations for Nuclear Medicine Physicians Regarding Breastfeeding Mothers. <i>Eur J Nucl Med</i>. 1995;22(5)BP17.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11108925">
<a name="11108925"></a>International Commission on Radiological Protection (ICRP). Pregnancy and Medical Radiation. <i>Ann ICRP</i>. 2000;30(1):iii-viii, 1-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-pyrophosphate-drug-information/abstract-text/11108925/pubmed" id="11108925" target="_blank">11108925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31107104">
<a name="31107104"></a>Mitchell KB, Fleming MM, Anderson PO, Giesbrandt JG; Academy of Breastfeeding Medicine. ABM Clinical Protocol #31: radiology and nuclear medicine studies in lactating women. <i>Breastfeed Med</i>. 2019;14(5):290‐294. doi:10.1089/bfm.2019.29128.kbm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-pyrophosphate-drug-information/abstract-text/31107104/pubmed" id="31107104" target="_blank">31107104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2645546">
<a name="2645546"></a>Mountford PJ, Coakley AJ. A Review of the Secretion of Radioactivity in Human Breast Milk: Data, Quantitative Analysis and Recommendations. <i>Nucl Med Commun</i>. 1989;10(1):15-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-pyrophosphate-drug-information/abstract-text/2645546/pubmed" id="2645546" target="_blank">2645546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8162938">
<a name="8162938"></a>Rubow S, Klopper J, Wasserman H, et al. The Excretion of Radiopharmaceuticals in Human Breast Milk: Additional Data and Dosimetry. <i>Eur J Nucl Med</i>. 1994;21(2):144-153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-pyrophosphate-drug-information/abstract-text/8162938/pubmed" id="8162938" target="_blank">8162938</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Society of Nuclear medicine (SNM). Society of Nuclear Medicine procedure guideline for general imaging. Version 6.0. Revised 2010. http://s3.amazonaws.com/rdcms-snmmi/files/production/public/docs/General_Imaging_Version_6.0.pdf. Accessed July 22, 2019.</div>
</li>
<li>
<div class="reference">
                  Technescan PYP kit for preparation [prescribing information]. Maryland Heights, MO: Curium US LLC; December 2018.</div>
</li></ol></div><div id="topicVersionRevision">Topic 16816 Version 74.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
